<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881110</url>
  </required_header>
  <id_info>
    <org_study_id>2_0401_2021</org_study_id>
    <nct_id>NCT04881110</nct_id>
  </id_info>
  <brief_title>Liraglutide and Peripheral Artery Disease</brief_title>
  <acronym>STARDUST</acronym>
  <official_title>Effects of the Glucagon Like-peptide 1 (GLP-1) Receptor Agonist Liraglutide on Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the&#xD;
      effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of&#xD;
      cardio-metabolic risk factors, in people with type 2 diabetes and peripheral artery disease.&#xD;
      The potential benefits for participants in the study include the possibility of improving&#xD;
      peripheral perfusion with drugs that have been evaluated as effective in controlling diabetes&#xD;
      and safe and protective for cardiovascular health.&#xD;
&#xD;
      The primary outcome of the study is the change of peripheral transcutaneous oxygen tension&#xD;
      between groups at three and six months. Participants in the study will be followed for 6&#xD;
      months in order to evaluate the effects of liraglutide and the change of other secondary&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral transcutaneous oxygen pressure</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Change in transcutaneous oxygen pressure (mmHg) on anterior and posterior tibial arteries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c Glucose control</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose control</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>fasting glucose differences between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI change</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference change</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure change</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Difference between groups in total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between groups in C reactive protein, fibrinogen, Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin (IL)-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Difference between groups in creatininemia, uremia, albuminuria level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenesis</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between groups in endothelial progenitors cells circulating levels and vascular endothelial growth factor (VEGF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial Index (ABI) change</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between groups in ABI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual hormonal profile</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between groups in sexual hormones levels [testosterone/estradiol, follicle stimulating hormone (FSH), luteinizing hormone (LH), SHBG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Male sexual function</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between groups in Erectile function (IIEF-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female sexual function</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between groups in Female sexual function (FSFI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Liraglutide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive liraglutide, according to the current clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.</description>
    <arm_group_label>Liraglutide group</arm_group_label>
    <other_name>Intervention group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of type 2 diabetes within at least 6 months&#xD;
&#xD;
          -  peripheral arterial disease documented within al least 1 year by doppler ultrasound,&#xD;
             angio-CT or arteriography&#xD;
&#xD;
          -  peripheral transcutaneous oxygen pressure between 30 and 49 mmHg on anterior and/or&#xD;
             posterior tibial arteries&#xD;
&#xD;
          -  Hba1c 6,5-8%&#xD;
&#xD;
          -  treatment of diabetes with metformin, insulin and/or sulfonylurea&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosis of type 1 diabetes&#xD;
&#xD;
          -  current treatment with GLP-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase -4&#xD;
             (DPP-4) inhibitors&#xD;
&#xD;
          -  GLP-1RAs allergy or intolerance&#xD;
&#xD;
          -  participation to other clinical studies&#xD;
&#xD;
          -  history of pancreatitis, thyroid disease, diabetic gastroparesis or inflammatory bowel&#xD;
             disease&#xD;
&#xD;
          -  current or planned pregnancy&#xD;
&#xD;
          -  acute myocardial infarction and/or acute cerebrovascular disease within 14 days from&#xD;
             the screening visit&#xD;
&#xD;
          -  planned revascularization procedure&#xD;
&#xD;
          -  renal function with estimated glomerular filtration rate (eGFR) below 15 ml/min&#xD;
&#xD;
          -  history of cancer and/or oncological treatment within 5 years from the screening visit&#xD;
&#xD;
          -  current treatment with corticosteroids&#xD;
&#xD;
          -  psychiatric or other clinical conditions which may interfere with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Esposito, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Esposito, MD, PhD</last_name>
    <phone>+39 0815665031</phone>
    <email>katherine.esposito@unicampania.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Esposito, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Katherine Esposito</investigator_full_name>
    <investigator_title>Professor of Endocrinology and Metabolic Diseases, Head of Unit of Diabetes</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Transcutaneous Oxygen Tension</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Diabetic microvascular complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

